JP2011520981A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520981A5
JP2011520981A5 JP2011510712A JP2011510712A JP2011520981A5 JP 2011520981 A5 JP2011520981 A5 JP 2011520981A5 JP 2011510712 A JP2011510712 A JP 2011510712A JP 2011510712 A JP2011510712 A JP 2011510712A JP 2011520981 A5 JP2011520981 A5 JP 2011520981A5
Authority
JP
Japan
Prior art keywords
agents
use according
leptin
composition
inflammatory drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011510712A
Other languages
English (en)
Japanese (ja)
Other versions
JP5622720B2 (ja
JP2011520981A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/044907 external-priority patent/WO2009143380A2/en
Publication of JP2011520981A publication Critical patent/JP2011520981A/ja
Publication of JP2011520981A5 publication Critical patent/JP2011520981A5/ja
Application granted granted Critical
Publication of JP5622720B2 publication Critical patent/JP5622720B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011510712A 2008-05-21 2009-05-21 神経原繊維変化に関連する進行性認知障害の治療方法 Active JP5622720B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5500908P 2008-05-21 2008-05-21
US61/055,009 2008-05-21
PCT/US2009/044907 WO2009143380A2 (en) 2008-05-21 2009-05-21 Methods for treating progressive cognitive disorders related to neurofibrillary tangles

Publications (3)

Publication Number Publication Date
JP2011520981A JP2011520981A (ja) 2011-07-21
JP2011520981A5 true JP2011520981A5 (enExample) 2012-07-05
JP5622720B2 JP5622720B2 (ja) 2014-11-12

Family

ID=41340901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011510712A Active JP5622720B2 (ja) 2008-05-21 2009-05-21 神経原繊維変化に関連する進行性認知障害の治療方法

Country Status (9)

Country Link
US (2) US8642543B2 (enExample)
EP (1) EP2326339A4 (enExample)
JP (1) JP5622720B2 (enExample)
KR (1) KR20110028457A (enExample)
CN (1) CN102099048A (enExample)
AU (1) AU2009248914A1 (enExample)
CA (1) CA2725143A1 (enExample)
WO (1) WO2009143380A2 (enExample)
ZA (1) ZA201008303B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
KR20110028457A (ko) * 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
CA2742600A1 (en) 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
EP3620154A1 (en) * 2009-02-06 2020-03-11 University Of Southern California Therapeutic compositions comprising monoterpenes
CN104744215B (zh) 2010-03-03 2019-03-15 尼昂克技术公司 包含单萜的药物组合物
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
US9499461B2 (en) 2010-08-27 2016-11-22 Neonc Technologies, Inc. Pharmaceutical compositions comprising POH derivatives
ES3056006T3 (en) 2010-12-17 2026-02-17 Univ Southern California Methods and devices for using isoperillyl alcohol
US20140088000A1 (en) * 2012-09-27 2014-03-27 Neurotez, Inc. Leptin Rescues Neurons from Alzheimer's Disease Related Pathways Triggered by Lipid Burden
WO2014165043A1 (en) * 2013-03-13 2014-10-09 Neurotez, Inc. Fragments, mutants and chimeric fusion proteins of leptin for treating alzheimer's disease
WO2016130800A2 (en) 2015-02-12 2016-08-18 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
CN110267538B (zh) 2016-11-30 2022-04-19 尼昂克技术公司 紫苏醇-3-溴丙酮酸缀合物和治疗癌症的方法
JP7325425B2 (ja) 2018-02-08 2023-08-14 ネオンク テクノロジーズ インク. 血液脳関門を透過性にする方法
WO2020182322A1 (en) 2019-03-14 2020-09-17 Om Pharma Sa Method of treating and/or preventing asthma, asthma exacerbations, allergic asthma and/or associated conditions with microbiota related to respiratory disorders
AU2021211012A1 (en) 2020-01-24 2022-08-25 Aim Immunotech Inc. Methods, compositions, and vaccines for treating a virus infection
CN114958760B (zh) * 2021-02-23 2024-04-26 南京启真基因工程有限公司 一种构建阿尔兹海默症模型猪的基因编辑技术及其应用

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
DK172541B1 (da) 1982-10-08 1998-12-07 Glaxo Group Ltd Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6048837A (en) 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US20020107211A1 (en) 1995-06-07 2002-08-08 The Rockefeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
JPH11501297A (ja) 1995-01-31 1999-02-02 イーライ・リリー・アンド・カンパニー 抗肥満症タンパク質
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
EP0725079A1 (en) 1995-01-31 1996-08-07 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US6068976A (en) 1995-03-20 2000-05-30 Ligand Pharmaceuticals Incorporated Modulators of ob gene and screening methods therefor
ES2093593T1 (es) 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
AU695934B2 (en) 1995-06-30 1998-08-27 Eli Lilly And Company Methods for treating diabetes
US5698389A (en) 1995-11-16 1997-12-16 Tularik, Inc. Transcriptional promoter of the murine obesity gene
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
IL124831A0 (en) 1995-12-27 1999-01-26 Genentech Inc Ob protein derivatives having prolonged half-life
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6025324A (en) 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
US5830450A (en) 1996-06-19 1998-11-03 Lallone; Roger L. Compositions of leptin bound to an apolipoprotein
US6630346B1 (en) 1996-06-20 2003-10-07 Merck & Co., Inc. Gene therapy for obesity
US6001816A (en) 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
EP0921820A4 (en) 1996-06-20 2003-01-15 Merck & Co Inc GENETERAPY FOR OBESITY
JP2002514904A (ja) 1996-06-20 2002-05-21 メルク エンド カンパニー インコーポレーテッド 肥満に対する遺伝子治療
US20060205660A1 (en) 1996-06-20 2006-09-14 Sauvage Frederic D OB protein-immunoglobulin chimeras
AU5654998A (en) 1996-12-06 1998-06-29 F. Hoffmann-La Roche Ag Muteins of obese protein
US20020019352A1 (en) 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
IL132380A0 (en) 1997-04-17 2001-03-19 Amgen Inc Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods
US6020004A (en) 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
EP0950417A3 (en) 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
JP4215857B2 (ja) * 1998-03-26 2009-01-28 裕 大村 学習・記憶能力改善剤
GB9807062D0 (en) 1998-04-02 1998-06-03 Imp College Innovations Ltd Immune response
CA2335107C (en) 1998-07-28 2010-01-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
CA2337667C (en) 1998-08-10 2008-04-29 Amgen Inc. Dextran-leptin conjugates, pharmaceutical compositions and related methods
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
CA2344623A1 (en) 1998-10-02 2000-04-13 Amgen Inc. Method to determine a predisposition to leptin treatment
US6716810B1 (en) 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
MXPA01005818A (es) 1998-12-09 2003-07-21 Eleanor Rooseveltl Inst Composicion y metodo para la regulacion del peso del cuerpo y condiciones asociadas.
MXPA01006922A (es) 1999-01-07 2002-04-24 Lexigen Pharm Corp Expresion y exportacion de proteinas de anti-obesidad como proteinas de fusion en fc.
EP1151102B1 (en) 1999-02-12 2006-04-19 Amgen Inc. Glycosylated leptin compositions and related methods
US20030215423A1 (en) 1999-04-01 2003-11-20 Merck & Co., Inc. Gene therapy for obesity
US6475984B2 (en) 1999-04-29 2002-11-05 The Nemours Foundation Administration of leptin
CA2376933A1 (en) 1999-06-11 2000-12-21 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
EP1210100B1 (en) * 1999-08-10 2006-06-14 UAB Research Foundation Method of treating traumatic brain using non-steroidal anti-inflammatory drugs
CA2382666A1 (en) 1999-08-23 2001-03-01 The Administrators Of The Tulane Educational Fund Modulation of the blood-brain barrier transporter for leptin
BR0107851A (pt) * 2000-01-24 2002-10-29 Innogenetics Nv Diagnose de tauopatia
US7582292B2 (en) 2000-02-26 2009-09-01 Artecel, Inc. Adipose tissue derived stromal cells for the treatment of neurological disorders
US20030049255A1 (en) * 2001-08-07 2003-03-13 Sims John E. Interleukin-1 receptors in the treatment of diseases
WO2003020303A1 (en) 2001-08-29 2003-03-13 The University Of Buckingham Use of leptin for infant with low birth weight for prevention of obesity
ATE475094T1 (de) 2001-10-22 2010-08-15 Amgen Inc Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung
EP2002827A2 (en) 2001-12-05 2008-12-17 The Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US7642281B2 (en) 2002-08-07 2010-01-05 Helicon Therapeutics, Inc. Indolone compounds useful to treat cognitive impairment
GB0323039D0 (en) * 2003-10-01 2003-11-05 Danisco Method
DE10353593A1 (de) 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
US7407929B2 (en) 2004-05-07 2008-08-05 Boston Biomedical Research Institute Leptin peptide antagonists
US20090088367A1 (en) 2004-05-10 2009-04-02 Burnham Institute For Medical Research Treatment of Insulin Resistance/Metabolic Syndrome to Alleviate the Risks of Dementia
US20050287519A1 (en) 2004-05-12 2005-12-29 Merchiers Pascal G Methods, compositions and compound assays for inhibiting amyloid-beta protein production
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US8043619B2 (en) 2004-10-08 2011-10-25 Yaron Ilan Methods and uses of leptin in immune modulation
US7307142B2 (en) 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US9333240B2 (en) 2005-09-16 2016-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compounds for improving nutritional status, cognition and survival
EP1795895A1 (en) 2005-12-08 2007-06-13 KeyNeurotek AG A tissue-based assay system for Alzheimer-specific degeneration and pathology
US20070218504A1 (en) 2006-03-09 2007-09-20 University Of Pittsburgh Human leptin-derived polypeptides and uses thereof
WO2007139818A2 (en) 2006-05-22 2007-12-06 The Board Of Trustees Of The Leland Stanford Junior University Pharmacological treatment of cognitive impairment
WO2008048691A2 (en) 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders
WO2008115880A2 (en) 2007-03-21 2008-09-25 The Board Of Regents Of The University Of Texas System Use of leptin for the treatment or prevention of parkinson's disease
WO2008155403A2 (en) 2007-06-20 2008-12-24 Universitat De Les Illes Balears Use of leptin in the prevention of unhealthy food habits and cardiovascular diseases
US8889622B2 (en) 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
US20090031434A1 (en) 2007-07-26 2009-01-29 Weiping Han Animal models for obesity and neurodegenerative diseases
EP2252314B1 (en) 2008-02-27 2014-04-09 Temple University - Of The Commonwealth System of Higher Education Leptin agonist and methods of use
WO2009138762A2 (en) 2008-05-15 2009-11-19 Regen Therapeutics Plc Therapeutic use of peptides
KR20110028457A (ko) 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
CA2742600A1 (en) 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta

Similar Documents

Publication Publication Date Title
JP2014517050A5 (enExample)
JP2005506370A5 (enExample)
JP2015524444A5 (enExample)
NZ593467A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
MY167423A (en) Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
JP2007533687A5 (enExample)
JP2014516942A5 (enExample)
JP2018168191A5 (enExample)
JP2022550919A5 (enExample)
JP2026016527A5 (enExample)
EP2832357A1 (en) Selective AT2 receptor agonists for use in treatment of cachexia
MX2024006271A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2016505050A5 (enExample)
JP2021514380A5 (ja) 筋障害及び骨障害を処置するための化合物及び組成物
JP2005512946A5 (enExample)
CN1976723B (zh) 制备治疗或预防感染性疾病的药物的用途
WO2010060742A1 (en) Combination of bifeprunox and an antipsychotic drug with d2/5-ht2a receptor antagonistic activity for treating cns disorders
JP2019507786A5 (enExample)
RU2013105513A (ru) Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи
JP2012502105A5 (enExample)
IL300144A (en) Benzazepines are combined for the treatment of Tourette syndrome
JP2015524460A5 (enExample)
JP2009545593A5 (enExample)
JP2015515971A5 (enExample)
CA3185939A1 (en) N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease